Director James M. Daly Files Initial Statement of Beneficial Ownership for Halozyme Therapeutics
HALOZYME THERAPEUTICS, INC.
Subscribe to track HALO
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
📋 Form 3: Initial Filing for Halozyme Therapeutics, Inc. ($HALO) Insider: Daly James M (Director) Event Date: September 28, 2026 Securities Owned: 0 shares reported (No securities beneficially owned) Significance: Low
Comprehensive Analysis
Executive Summary
On October 2, 2026, James M. Daly filed an initial Form 3 with the SEC indicating his status as a director of Halozyme Therapeutics, Inc. (HALO). The filing indicates that, as of the event date of September 28, 2026, Mr. Daly beneficially owned zero securities of the company.
Key Details
- Reporting Person: James M. Daly
- Role: Director
- Company: Halozyme Therapeutics, Inc. (
HALO) - Event Date: September 28, 2026
- Filing Date: October 2, 2026
- Holdings: No equity or derivative securities owned (
<noSecuritiesOwned>1</noSecuritiesOwned>)
Significance & Market Impact
This is a routine initial ownership disclosure following Mr. Daly's appointment or qualification as a director. Because no open-market transactions or direct shareholdings were reported, this filing carries low informational and market trading significance.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.